ENZN Enzon Inc (QX)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * COUCHMAN JONATHAN	2. Issuer Name and Ticker or Trading Symbol ENZON PHARMACEUTICALS, INC. [ ENZN ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    __X__ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) 600 FIFTH AVENUE, 2ND FLOOR	3. Date of Earliest Transaction (MM/DD/YYYY) 3/13/2020
(Street) NEW YORK, NY 10020 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY) 3/27/2020	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value (1)	3/13/2020		P		19709	A	$0.135	1594232	I	By Xstelos Corp. (2)
Common Stock, $0.01 par value (1)	3/23/2020		P		2678	A	$0.14	2928	I	By Myrexis, Inc. (4)
Common Stock, $0.01 par value (1)	3/25/2020		P		469551	A	$0.14	472479	I	By Myrexis, Inc. (4)
Common Stock, $0.01 par value (1)	3/26/2020		P		160785	A	$0.14	633264	I	By Myrexis, Inc. (4)
Common Stock, $0.01 par value (1)								4717666	D
Common Stock, $0.01 par value (1)								400000	I	By Couchman Family Fund (3)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:
(1)	This Form 4 is filed jointly by Jonathan Couchman ("Mr. Couchman"), Couchman Family Fund (the "Foundation"), Xstelos Corp. ("Xstelos") and Myrexis, Inc. ("Myrexis" and, together with Mr. Couchman, the Foundation and Xstelos, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Shares for purposes of Section 16 or for any other purpose.
(2)	Represents Shares owned directly by Xstelos. Mr. Couchman is the controlling shareholder and Chief Executive Officer of Xstelos. By virtue of these relationships, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Xstelos. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
(3)	Represents Shares owned directly by the Foundation. Mr. Couchman is the sole trustee of the Foundation. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by the Foundation, however he has no pecuniary interest in such Shares.
(4)	Represents Shares owned directly by Myrexis. Mr. Couchman is Chief Executive Officer of Myrexis. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Myrexis. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.

Remarks: This amended Form 4 is filed on behalf of the Reporting Persons because as of the original filing date, Myrexis did not have the necessary SEC filing codes. Myrexis has since obtained the necessary filing codes and the Reporting Persons are filing this amendment accordingly.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
COUCHMAN JONATHAN 600 FIFTH AVENUE 2ND FLOOR NEW YORK, NY 10020		X
Couchman Family Fund 600 FIFTH AVENUE 2ND FLOOR NEW YORK, NY 10020				See Footnote 1
Xstelos Corp. 600 FIFTH AVENUE 2ND FLOOR NEW YORK, NY 10020				See Footnote 1
Myrexis, Inc. 600 FIFTH AVENUE, 2ND FLOOR NEW YORK, NY 10020				See Footnote 1

Signatures
/s/ Jonathan Couchman		3/31/2020
**Signature of Reporting Person		Date
Couchman Family Fund; By: /s/ Jonathan Couchman, Trustee		3/31/2020
**Signature of Reporting Person		Date
Xstelos Corp.; By: /s/ Jonathan Couchman, Chief Executive Officer		3/31/2020
**Signature of Reporting Person		Date
Myrexis, Inc.; By: /s/ Jonathan Couchman, Chief Executive Officer		3/31/2020
**Signature of Reporting Person		Date